Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Catalyst Grant: STBBI Research in Canada: Beyond HIV/AIDS/Hepatitis C - General

University of Calgary

$100,000.00

Development of a Canadian Hepatitis B Virtual Centre of Excellence

EF 2021-22

Résumé
The hepatitis B virus (HBV) is the leading global cause of end-stage liver disease, cirrhosis and hepatocellular carcinoma (HCC or primary liver cancer). The management of hepatitis B is often complex and depends upon identifying patients at risk, appropriate diagnostic workup, treatment and follow-up. CHB affects ~260,000 Canadians but disease prevalence and the burden of associated liver disease is expected to increase due to the impact of immigration and an aging population. Despite the availability of potent oral antiviral therapy, persons living with HBV remain at risk for progressive liver disease due to suboptimum linkage to care and low treatment uptake. There is an urgent need for systematic research to identify gaps in the HBV care continuum, improve access to therapy and reduce the risk of HBV-related end-stage liver disease. The Canadian HBV Network is well-established with key infrastructure to help improve the HBV care continuum in Canada. This catalyst grant funding will spearhead an initiative to determine barriers in the linkage to HBV care and access to treatment in patients followed by the Canadian HBV Network. We will (i) conduct a pilot study to describe diagnostic workup, referral patterns, the proportion referred to tertiary care, and those who receive HBV antiviral treatment, (ii) conduct survey studies and focus groups of patients, primary care providers and hepatitis B specialists to inform development of strategies that facilitate access to care and treatment and (iii) develop working groups to inform a larger team grant to enhance collaborations on HBV research, training and improve access to care for hepatitis B in Canada. The PI and co-PIs can engage patients and stakeholders through established collaborations, and have expertise in hepatitis B and/or required research methodology. Our studies will help understand and predict the risk of liver disease related to hepatitis B an often devastating liver disease.
Programme
Catalyst Grant: STBBI Research in Canada: Beyond HIV/AIDS/Hepatitis C - General
Bénéficiaire
Emplacement
Alberta, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
453439
Name
Coffin Carla S
Region
Alberta
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Infection and Immunity
Theme2
Biomedical
Prcname2
Catalyst Grant - STBBI Research in Canada: Beyond HIV/AIDS and Hepatitis C
Projecttitle
Development of a Canadian Hepatitis B Virtual Centre of Excellence
Programtype2
Operating Grants
Orgnameinp2
University of Calgary
Cihramount2
$100,000
Cihrequipment2
$0
Programname2
Catalyst Grant: STBBI Research in Canada: Beyond HIV/AIDS/Hepatitis C - General
Keyworddelim
Antiviral Treatment; Canadian Hbv Network; Centre Of Excellence; Chronic Hepatitis B Infection; Cirrhosis; Health Services; Hepatitis B Virus; Hepatocellular Carcinoma; Liver Disease; Survey
Abstract
The hepatitis B virus (HBV) is the leading global cause of end-stage liver disease, cirrhosis and hepatocellular carcinoma (HCC or primary liver cancer). The management of hepatitis B is often complex and depends upon identifying patients at risk, appropriate diagnostic workup, treatment and follow-up. CHB affects ~260,000 Canadians but disease prevalence and the burden of associated liver disease is expected to increase due to the impact of immigration and an aging population. Despite the availability of potent oral antiviral therapy, persons living with HBV remain at risk for progressive liver disease due to suboptimum linkage to care and low treatment uptake. There is an urgent need for systematic research to identify gaps in the HBV care continuum, improve access to therapy and reduce the risk of HBV-related end-stage liver disease. The Canadian HBV Network is well-established with key infrastructure to help improve the HBV care continuum in Canada. This catalyst grant funding will spearhead an initiative to determine barriers in the linkage to HBV care and access to treatment in patients followed by the Canadian HBV Network. We will (i) conduct a pilot study to describe diagnostic workup, referral patterns, the proportion referred to tertiary care, and those who receive HBV antiviral treatment, (ii) conduct survey studies and focus groups of patients, primary care providers and hepatitis B specialists to inform development of strategies that facilitate access to care and treatment and (iii) develop working groups to inform a larger team grant to enhance collaborations on HBV research, training and improve access to care for hepatitis B in Canada. The PI and co-PIs can engage patients and stakeholders through established collaborations, and have expertise in hepatitis B and/or required research methodology. Our studies will help understand and predict the risk of liver disease related to hepatitis B an often devastating liver disease.
Competitiondate
202106
Approvedterm2
1 yr 0 mth
Pinamesdelim
Coffin, Carla S
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $100,000~ $0~